Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents

Schafer DF and Sorrell MF: Hepatocellular carcinoma. Lancet. 353:1253–1257. 1999. View Article : Google Scholar : PubMed/NCBI

Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:505–515. 2000. View Article : Google Scholar : PubMed/NCBI

Guo RP, Zhong C, Shi M, et al: Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 132:547–555. 2006. View Article : Google Scholar : PubMed/NCBI

Iavarone M, Lampertico P, Iannuzzi F, et al: Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat. 14:133–139. 2007. View Article : Google Scholar : PubMed/NCBI

Li CY, Shan S, Huang Q, et al: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 92:143–147. 2000. View Article : Google Scholar

Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar

Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808–812. 1999. View Article : Google Scholar : PubMed/NCBI

Brandvold KA, Neiman P and Ruddell A: Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene. 19:2780–2785. 2000. View Article : Google Scholar : PubMed/NCBI

Yoshiji H, Kuriyama S, Yoshii J, et al: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology. 39:1517–1524. 2004. View Article : Google Scholar : PubMed/NCBI

Frachon S, Gouysse G, Dumorti J, et al: Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol. 34:850–857. 2001. View Article : Google Scholar : PubMed/NCBI

Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI

Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI

Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI

Eskens FA and Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer. 42:3127–3139. 2006. View Article : Google Scholar

Verheul HM and Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI

Berenson A: A cancer drug shows promise, at a price that many can’t pay. The New York Times. A1:C22006.PubMed/NCBI

Yoshiji H, Kuriyama S, Noguchi R, et al: Combination of vitamin K(2) and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol. 42:687–693. 2005. View Article : Google Scholar

Yoshiji H, Noguchi R, Yamazaki M, et al: Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J Gastroenterol. 13:3259–3261. 2007.

Yoshiji H, Noguchi R, Toyohara M, et al: Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol. 51:315–321. 2009. View Article : Google Scholar

Murukesh N, Dive C and Jayson GC: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 102:8–18. 2010. View Article : Google Scholar : PubMed/NCBI

Kokudo N and Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol. 44:119–121. 2009. View Article : Google Scholar : PubMed/NCBI

Makuuchi M, Kokudo N, Arii S, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 38:37–51. 2008. View Article : Google Scholar : PubMed/NCBI

Okita K: Management of hepatocellular carcinoma in Japan. J Gastroenterol. 41:100–106. 2006. View Article : Google Scholar

Ferrara N: VEGF as a therapeutic target in cancer. Oncology. 69(Suppl 3): 11–16. 2005. View Article : Google Scholar

Dowlati A, Gray R, Sandler AB, Schiller JH and Johnson DH: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab – an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 14:1407–1412. 2008.

Nagaoka S, Yoshida T, Akiyoshi J, et al: The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep. 23:1647–1654. 2010.

Yoshiji H, Kuriyama S, Yoshii J, et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 35:834–842. 2002. View Article : Google Scholar : PubMed/NCBI

Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E and Urbanska-Rys H: Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw. 14:149–153. 2003.PubMed/NCBI

Corradini SG, Morini S, Liguori F, et al: Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein. Liver Int. 29:103–112. 2009. View Article : Google Scholar

Deprimo SE, Bello CL, Smeraglia J, et al: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 5:322007. View Article : Google Scholar : PubMed/NCBI